This site provides INTERCEPT product information for Health Care Professionals in the United States. Learn more

Cerus Websites
INTERCEPT PLATELETS

Protects Patients

Protect Patients* with Proven Safety and Efficacy

Help protect your patients with reduced transfusion-transmitted infection (TTI) and transfusion-associated graft-versus-host disease (TA-GVHD) risks while providing therapeutically effective platelets.1 The safety and efficacy of platelets treated with the INTERCEPT® Blood System Pathogen Reduction System (INTERCEPT Platelets) are supported by hemovigilance (HV) programs and clinical trials.

Demonstrated prevention of septic transfusion reactions in routine use

HV programs provide a comprehensive view of transfusions and potential adverse events via the surveillance of blood donations in routine use settings. Over 2.4 million INTERCEPT Platelet units have been transfused in French, Swiss, and Belgium national HV programs, with significantly reduced TTIs and no fatalities attributed to INTERCEPT Platelets.2-7

Conventional Platelets
Conventional Platelets
Intercept Platelets
Intercept Platelets
HV Program
Units Transfused (n)
TTIs (Fatalities)
Units Transfused (n)
TTIs (Fatalities)
France 2006-2021
2,832,026
55 (9)
1,622,704
1 (0)‡
Switzerland 2005-2021
156,809
13 (3)
397,941
0 (0)
Belgium 2009-2018
252,809
9 (0)
428,091
1 (0)†
Total
3,241,644
77 (12)
2,443,776
2 (0)

†Belgium 2018: Staphylococcus hominis was reported in a patient who recovered. This case was not thoroughly investigated for modes of contamination via storage container leaks or other environmental sources.8 ‡France 2021: Bacillus cereus transmission was reported in a patient who recovered. B. cereus is a spore-forming bacteria; the spore form is resistant to INTERCEPT.9

Proven therapeutic efficacy through numerous clinical trials

The INTERCEPT Blood System has been evaluated in clinical trials in which over 2000 patients received INTERCEPT Platelets. Primary endpoints were met, including bleeding criteria, a measure of hemostatic efficacy.

Study
Patients
Design
Primary Endpoint
Primary Endpoint met?
Safety of INTERCEPT Platelets, hem/onc patients10
2291
Prospective, open-label, non-randomized, sequential, two-cohort
Incidence of TE-AMV
Safety/efficacy of INTERCEPT Platelets, thrombocytopenic patients11
645
Randomized, double-blind, parallel
WHO Grade 2 Bleeding
Viability of INTERCEPT Platelets, clearance of amotosalen, healthy patients12-13
65
Randomized, single-blind, cross-over
Recovery/survival, clearance of amatosalen
Safety/efficacy of INTERCEPT Platelets, thrombocytopenic patients14
43
Randomized, double-blind, parallel
1 Hour CCI
Safety/efficacy of INTERCEPT Platelets, thrombocytopenic patients15
32
Randomized, double-blind, cross-over
Bleeding time

You  may also be interested in View all 

Why Blood Safety Matters
Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study
Watch the video
Elevate Patient Care
INTERCEPT Platelets Publications
Learn more
Mechanism of Action
Why INTERCEPT: Non-Infectious Risk
Read more

*There is no pathogen reduction process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19, and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, see Package Insert.

References:

  1. The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation.
  2. Cazenave, JP, et al. Pathogen Inactivation of Platelets. AABB Press: Bethesda, MD 2013; 19-176.
  3. 
French National Agency for Medicine and Health Product Safety/ANSM, Activity Reports, 2009–2021.
  4. 
SwissMedic Haemovigilance Annual Reports, 2005–2021.
  5. Benjamin et al. Transfusion 2017; 57:2946-57.
  6. 
Jutzi M. et al. Transfus Med Hemother 2018; 45:151-6.
  7. 
AFMPS Hémovigilance Rapport annuel: Belgium. 2016-2018.
  8. 
Gammon RR, et al. Transfusion 2022 Mar; 62(3):641-650.
  9. Lefort, C, et al. Transfusion Clinique et Biologique 2022;29:338.
  10. Snyder, EL, et al. Transfusion. 2022; 62( 7): 1365–1376.
  11. McCullough et al: Blood 2004;104(5):1534-1541.
  12. Snyder E et al. Transfusion 2004;44:1732-1740.
  13. Corash L et al.Transfusion 2000;40(S10):137.
  14. Janetzko et al. Transfusion 2005;45:1443-1452.
  15. Slichter SJ et al. Transfusion 2006; 46(5):731-740.